Lonza Group AG

“Lonza is structurally the strongest Western biologics CDMO — regulatory switching costs, BIOSECURE Act tailwinds, and a 10–15 year secular growth runway are genuine and durable. The problem is price: at ~22x forward earnings with ROIC still sub-cost-of-capital, 4x net leverage, and three CEOs in five years, the stock already prices in a clean execution path that management has not yet earned the right to promise. Permanent impairment risk is low; pedestrian 5-year returns are probable. Track for a better entry in the CHF 380–420 range where the margin of safety would be adequate.”